RxDoctor Payments Data

Khursheed Banglawala, MD

Family Medicine · Pearland, TXNPI 1720035546

Payments from drug & device makers

$1,303in general payments, 2019–2025

Across 47 payments — averaging $27.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$314
  • Novo Nordisk$205
  • Inari Medical, Inc.$140
  • Sanofi$125
  • Pfizer$75
  • GSK$58
  • plus $386 from 15 others

What the payments were for

  • Food & beverage$1,297100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,303 in reported general payments places this provider in the 65th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$41,323
Medicare patients
85
Services billed
512

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide77$90,346
OzempicSemaglutide24$28,114
JardianceEmpagliflozin15$27,714
Rosuvastatin Calcium124$1,512
SynthroidLevothyroxine Sodium13$1,471
Atorvastatin Calcium164$1,400
Metoprolol Succinate65$1,179
Amlodipine Besylate140$1,093
Duloxetine Hcl31$1,014
Levothyroxine Sodium80$839
Gabapentin53$782
Pregabalin24$601
Estradiol11$564
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide18$536
Albuterol Sulfate HfaAlbuterol Sulfate24$480

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$44$90,34677 claims
Novo NordiskOzempic$205$28,11424 claims
Boehringer IngelheimJardiance$12$27,71415 claims
AbbVieSynthroid$18$1,47113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Pearland

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →